---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-26-000013"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2026-01-28T23:59:59+00:00"
generated_at: "2026-05-16T06:59:20.009641+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nurix reports FY2025 net loss of $264.5M; initiates DAYBreak registrational program for bexobrutideg

## Summary
- FY2025 revenue $84.0M (+54% YoY); net loss $264.5M ($3.05/sh) vs $193.6M ($2.88/sh) last year.
- Bexobrutideg Phase 1 in r/r CLL: 83% ORR, median PFS 22.1 months; DAYBreak pivotal Phase 2 initiated at 600 mg.
- Completed $250M stock offering in Oct 2025; cash, cash equivalents & marketable securities $592.9M.
- Appointed Roger Dansey to Board; Phase 3 randomized trial vs pirtobrutinib expected H1 2026.
- Preclinical IRAK4 degrader GS-6791 data presented; Phase 1 HV study ongoing; autoimmune IND planned 2026.

## SEC filing metadata
- accession: 0001549595-26-000013
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2026-01-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000013/0001549595-26-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000013/nrix-20260128.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-26-000013
- JSON: https://secwatch.observer/filing/0001549595-26-000013.json
- Plain text: https://secwatch.observer/filing/0001549595-26-000013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.